Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

622 results
Display

A general view of CD33⁺ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy

Fathi E, Farahzadi , Sheervalilou R, Sanaat Z, Vietor I

Acute myeloblastic leukemia (AML) is the most frequent acute leukemia in adulthood with very poor overall survival rates. In the past few decades, significant progresses had led to the findings...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study

Kim SH, Lee DE, Joung JY, Seo HK, Lee KH, Chung J

PURPOSE: This study aimed to compare progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) in Heng intermediate-risk patients with metastatic renal cell carcinoma (mRCC) treated with first-line immunotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?

Lee HW, Cho KJ, Park JY

Most patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage of disease. Until recently, systemic treatment options that showed survival benefits in HCC have been limited to tyrosine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives

Lim SM, Hong MH, Kim HR

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis

Oh SJ, Lee J, Kim Y, Song KH, Cho E, Kim M, Jung H, Kim TW

Cancer immunotherapy, in the form of vaccination, adoptive cellular transfer, or immune checkpoint inhibitors, has emerged as a promising practice within the field of oncology. However, despite the developing field's...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy

Kim JH, Kim BS, Lee SK

Tregs have a role in immunological tolerance and immune homeostasis by suppressing immune reactions, and its therapeutic potential is critical in autoimmune diseases and cancers. There have been multiple studies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy

Jeong S, Park SH

Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Re-defining T-Cell Exhaustion: Subset, Function, and Regulation

Im SJ, Ha SJ

Acute viral infection or vaccination generates highly functional memory CD8 T cells following the Ag resolution. In contrast, persistent antigenic stimulation in chronic viral infection and cancer leads to a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B vaccination and immunotherapies: an update

Stasi C, Silvestri , Voller F

World Health Organization (WHO) estimates that 257 million people were living with chronic hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western Pacific Region (6.2%)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Status of Immunotherapy for Lung Cancer and Future Perspectives

Kim HC, Choi CM

Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recurrent cervicocephalic artery dissection in a patient with Churg-Strauss syndrome treated with long-term corticosteroid therapy

Kim HJ, Park SR, Bang OY

Churg-Strauss syndrome (CSS) is known to mainly involve small vessels; thus, in the event of large-vessel disease, other causes must be taken into consideration. We report a case of CSS...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Combined biomarker for prediction of response to an immune checkpoint inhibitor in metastatic gastric cancer

Heo YJ, Kang SY, Kim ST, Kang WK, Lee J, Kim KM

PURPOSE: Immune checkpoint blockades (ICB) have been successful in gastric cancer (GC). However, the majority of unselected patients with GC fail to respond to ICB. It is crucial to identify...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diagnosis and Treatment of Gastric Mucosa-associated Lymphoid Tissue Lymphoma

Gong EJ, Choi KD

The stomach is the most common primary site of an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type, which is characterized by an indolent clinical course. A diagnosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
PD-1: A Negative Regulator of Phagocytosis by Tumour-Associated Macrophages in Colon Cancer

Islam Tultul MS, Koh YS

Programmed cell death protein 1 (PD-1) is an immuno-inhibitory cell surface receptor protein of the myeloid, and lymphoid cell. PD-L1 is the ligand of PD-1, which is abundant in different...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluating Antitumor Activity of Kiatomab by Targeting Cancer Stem Cell-Specific KIAA1114 Antigen in Mice

Kim SW, Park HW, Kim H, Lee S, Choi SY, Park Y, Lee SW

A full-length translational product of the trophinin gene, KIAA1114, is a distinctive marker of cancer stem cells in human hepatocellular carcinoma, and a mAb, Kiatomab, is specific to KIAA1114 antigen....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity

Oh SJ, Lee JK, Shin OS

Immunosenescence is characterized by a progressive deterioration of the immune system associated with aging. Multiple components of both innate and adaptive immune systems experience aging-related changes, such as alterations in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists

Chang S, Park HK, Choi YL, Jang SJ, Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists

BACKGROUND: Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cancer Immunotherapy Related Endocrine Adverse Effects

Kim H, Cho SW, Park YJ

Cancer immunotherapy has emerged as a promising therapy for a wide variety of tumors. Immune checkpoint inhibitors including anti cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors

Lee KA, Kim HR, Yoon SY

Immune checkpoint inhibitors (ICIs) have revolutionized anticancer therapy due to their long-term clinical benefits and immune boosting mechanisms. However, despite their consistent therapeutic effects, the use of ICIs is associated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of Serum Vitamin D and Efficacy of Subcutaneous Immunotherapy in Adult Patients With Allergic Rhinitis

Joudi M, Farid Hosseini R, Khoshkhui , Salehi M, Kouzegaran S, Ahoon M, Jabbari Azad F

Immunotherapy is the standard of treatment for long-life relief of symptoms of allergic rhinitis. Vitamin D may affect the outcomes of treatment. This study evaluated the clinical efficacy of subcutaneous...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr